Neuraxpharm has launched two new treatments for attention deficit hyperactivity disorder (ADHD) in Europe: Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) prolonged-release tablets. The launches are aimed at providing flexible dosing options for children and adolescents aged 6–17 years.

Tuzulby, developed by Tris Pharma and available in Germany, the UK, and Nordic countries since December 2025, is the first once-daily prolonged-release chewable methylphenidate tablet in Europe. The formulation allows individualised dosing and is designed to support treatment adherence, particularly in children who may have difficulty swallowing conventional tablets. Further European launches are planned in the coming months.

Paxneury, launched in September across multiple European countries, is a second-line ADHD treatment for children and adolescents for whom stimulants are not suitable, tolerated, or effective. The formulation offers higher doses of 5mg, 6mg, and 7mg, representing the first generic prolonged-release guanfacine available in Europe. It allows flexible dosing based on patient response and tolerability.

Dr. Jörg Thomas Dierks, ceo of Neuraxpharm, said: “With these launches, we are proud to deliver two differentiated solutions that expand treatment choice and flexibility for prescribing doctors. These product offerings reflect our ongoing strategy to make a range of innovative CNS therapies widely available across Europe.”

ADHD is a neurodevelopmental disorder characterised by impaired attention, disorganization, and hyperactivity-impulsivity. Approximately 5% of children and adolescents in Europe are affected by the condition.

The launches are part of Neuraxpharm’s broader strategy to advance ADHD care across Europe by offering therapies designed to improve adherence and allow personalised treatment, while supporting families and healthcare providers in managing the condition.